BioLife Solns Analyst Ratings
BioLife Solns Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2023 | 88.76% | Craig-Hallum | $29 → $23 | Maintains | Buy |
| 08/09/2023 | 105.17% | TD Cowen | $29 → $25 | Maintains | Outperform |
| 08/09/2023 | 105.17% | Lake Street | $34 → $25 | Maintains | Buy |
| 07/17/2023 | 138% | Stephens & Co. | $27 → $29 | Maintains | Overweight |
| 07/11/2023 | 138% | Craig-Hallum | → $29 | Initiates Coverage On | → Buy |
| 03/17/2023 | 121.58% | Stephens & Co. | $31 → $27 | Maintains | Overweight |
| 03/06/2023 | 129.79% | Oppenheimer | → $28 | Reiterates | → Outperform |
| 05/10/2022 | 228.27% | Stephens & Co. | $47 → $40 | Maintains | Overweight |
| 05/10/2022 | 146.2% | Keybanc | $60 → $30 | Maintains | Overweight |
| 04/25/2022 | 129.79% | Oppenheimer | → $28 | Upgrades | Perform → Outperform |
| 08/13/2021 | 392.41% | Keybanc | $50 → $60 | Maintains | Overweight |
| 05/14/2021 | — | Benchmark | Downgrades | Buy → Hold | |
| 03/23/2021 | 343.17% | Benchmark | → $54 | Upgrades | Hold → Buy |
| 03/23/2021 | 310.34% | KeyBanc | $40 → $50 | Maintains | Overweight |
| 11/10/2020 | 228.27% | Keybanc | → $40 | Initiates Coverage On | → Overweight |
| 09/22/2020 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 09/18/2020 | 170.82% | Cowen & Co. | → $33 | Initiates Coverage On | → Outperform |
| 08/11/2020 | — | Benchmark | Downgrades | Buy → Hold | |
| 05/04/2020 | 80.55% | B. Riley Securities | $24 → $22 | Maintains | Buy |
| 03/23/2020 | 39.52% | HC Wainwright & Co. | $26 → $17 | Maintains | Buy |
| 03/12/2020 | 96.96% | B. Riley Securities | $27 → $24 | Maintains | Buy |
| 02/24/2020 | 105.17% | Lake Street | → $25 | Initiates Coverage On | → Buy |
| 02/19/2020 | 96.96% | Benchmark | → $24 | Initiates Coverage On | → Buy |
| 02/06/2020 | 121.58% | B. Riley Securities | → $27 | Initiates Coverage On | → Buy |
| 12/16/2019 | 113.38% | HC Wainwright & Co. | $23 → $26 | Reiterates | → Buy |
| 11/21/2019 | 80.55% | Oppenheimer | → $22 | Initiates Coverage On | → Outperform |
| 09/04/2019 | 80.55% | Northland Capital Markets | $18 → $22 | Maintains | Outperform |
| 07/22/2019 | 88.76% | HC Wainwright & Co. | → $23 | Initiates Coverage On | → Buy |
| 10/03/2018 | 80.55% | B. Riley Securities | $23 → $22 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月10日 | 88.76% | 克雷格-哈勒姆 | $29→$23 | 維護 | 買 |
| 08/09/2023 | 105.17% | TD Cowen | $29→$25 | 維護 | 跑贏大盤 |
| 08/09/2023 | 105.17% | 萊克街 | $34→$25 | 維護 | 買 |
| 07/17/2023 | 138% | 斯蒂芬斯公司 | $27→$29 | 維護 | 超重 |
| 07/11/2023 | 138% | 克雷格-哈勒姆 | →$29 | 開始承保 | →購買 |
| 03/17/2023 | 121.58% | 斯蒂芬斯公司 | $31→$27 | 維護 | 超重 |
| 03/06/2023 | 129.79% | 奧本海默 | →$28 | 重申 | →跑贏大盤 |
| 2022年05月10日 | 228.27% | 斯蒂芬斯公司 | $47→$40 | 維護 | 超重 |
| 2022年05月10日 | 146.2% | KeyBanc | $60→$30 | 維護 | 超重 |
| 04/25/2022 | 129.79% | 奧本海默 | →$28 | 升級 | →表現強於大盤 |
| 2021/08/13 | 392.41% | KeyBanc | $50→$60 | 維護 | 超重 |
| 2021/05/14 | - | 基準 | 評級下調 | 購買→Hold | |
| 03/23/2021 | 343.17% | 基準 | →$54 | 升級 | 持有→購買 |
| 03/23/2021 | 310.34% | KeyBanc | $40→$50 | 維護 | 超重 |
| 11/10/2020 | 228.27% | KeyBanc | →$40 | 開始承保 | →超重 |
| 09/22/2020 | - | 奧本海默 | 評級下調 | 超越→表現 | |
| 09/18/2020 | 170.82% | 考恩公司 | →$33 | 開始承保 | →跑贏大盤 |
| 2020年08月11日 | - | 基準 | 評級下調 | 購買→Hold | |
| 05/04/2020 | 80.55% | B.萊利證券 | $24→$22 | 維護 | 買 |
| 03/23/2020 | 39.52% | HC Wainwright公司 | $26→$17 | 維護 | 買 |
| 03/12/2020 | 96.96% | B.萊利證券 | $27→$24 | 維護 | 買 |
| 02/24/2020 | 105.17% | 萊克街 | →$25 | 開始承保 | →購買 |
| 02/19/2020 | 96.96% | 基準 | →$24 | 開始承保 | →購買 |
| 02/06/2020 | 121.58% | B.萊利證券 | →$27 | 開始承保 | →購買 |
| 2019年12月16日 | 113.38% | HC Wainwright公司 | $23→$26 | 重申 | →購買 |
| 2019年11月21日 | 80.55% | 奧本海默 | →$22 | 開始承保 | →跑贏大盤 |
| 2019年09月04日 | 80.55% | 北國資本市場 | $18→$22 | 維護 | 跑贏大盤 |
| 2019年07月22日 | 88.76% | HC Wainwright公司 | →$23 | 開始承保 | →購買 |
| 10/03/2018 | 80.55% | B.萊利證券 | $23→$22 | 維護 | 買 |
What is the target price for BioLife Solns (BLFS)?
BioLife Solns(BLFS)的目標價格是多少？
The latest price target for BioLife Solns (NASDAQ: BLFS) was reported by Craig-Hallum on August 10, 2023. The analyst firm set a price target for $23.00 expecting BLFS to rise to within 12 months (a possible 88.76% upside). 7 analyst firms have reported ratings in the last year.
克雷格-哈勒姆於2023年8月10日報道了BioLife Solns(納斯達克：BLFS)的最新目標價。這家分析公司將目標價定為23.00美元，預計BLFS將在12個月內升至(可能上漲88.76%)。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for BioLife Solns (BLFS)?
BioLife Solns(BLFS)的最新分析師評級是多少？
The latest analyst rating for BioLife Solns (NASDAQ: BLFS) was provided by Craig-Hallum, and BioLife Solns maintained their buy rating.
納斯達克(Sequoia Capital：BLFS)的最新分析師評級由Craig-Hallum提供，BioLife Solns維持買入評級。
When is the next analyst rating going to be posted or updated for BioLife Solns (BLFS)?
BioLife Solns(BLFS)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioLife Solns, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioLife Solns was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與BioLife Solns的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。BioLife Solns的上一次評級是在2023年8月10日提交的，所以你應該預計下一次評級將在2024年8月10日左右的某個時候公佈。
Is the Analyst Rating BioLife Solns (BLFS) correct?
分析師對BioLife Solns(BLFS)的評級正確嗎？
While ratings are subjective and will change, the latest BioLife Solns (BLFS) rating was a maintained with a price target of $29.00 to $23.00. The current price BioLife Solns (BLFS) is trading at is $12.19, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的BioLife Solns(BLFS)評級維持不變，目標價在29.00美元至23.00美元之間。BioLife Solns目前的股價為12.19美元，超出了分析師的預期區間。